ArticleMolecular diversity2026
Synthesis, radiolabelling and preliminary evaluation of [
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cyanuric chloride is a highly reactive, widely recognized compound in medicinal chemistry, enabling rapid and selective nucleophilic substitution reactions at its three chlorine positions. In the present study, explore the structural advantages of cyanuric chloride to develop a new DOTA-linked triazine-based scaffold for PSMA. Two scaffolds, abbreviated as PSMA-C1D and PSMA-C2D, were successfully synthesized with good yields and evaluated their properties through molecular docking, in vitro studies, radiolabelling, physicochemical properties, and internalization studies. The initial screening revealed that, the PSMA-C1D had greater potential as a PSMA-targeted imaging agent than PSMA-C2D. In vitro cytotoxicity assays further indicated good biocompatibility at imaging-relevant concentrations. The molecular docking demonstrated strong site-specific binding of PSMA-C1D to the PSMA active pocket (ΔG = - 10.2 kcal/mol), with interactions closely resembling the co-crystallized ligand. The radiolabelling of PSMA-C1D with Ga-68 shows high yield with > 95% radiochemical purity, excellent stability in multiple biological media, and high apparent molar activity (508 GBq/µmol). The tracer shows hydrophilicity (logD
Indexed as
Identifiers
42069839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.